retatrutide liver disease Researchers report promising results with retatrutide, which significantly reduced fat in some patients over several months. Excess liver fat causes metabolic dysfunction–associated steatotic liver (MASLD), formerly fatty liver disease. This Experimental weight-loss drug slashed fat

suspected reactions should be reported via the MHRA Yellow Card scheme

Our Olympia, Washington experts work with you to develop a holistic plan that integrates medication with healthy living

The Medicare GLP-1 Bridge launched July 1, 2026, offering $50/month copays for eligible Part D beneficiaries through December 2027

When tirzepatide was in Phase 3 trials (2020-2022), Lilly similarly did not disclose the KwikPen format ahead of approval

If youre confused about what clear liquids are, youre not alone

How PlexusDx Supports a More Personalized Approach PlexusDx genetic insights reveal predispositions in key peptide receptor genesGLP1R, GIPR, and MC4R variantsthat may help provide context for how your body processes GLP-1 and dual-agonist medications